Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prognostic markers in acute leukemia

C P Leith1, C L Willman

  • 1University of New Mexico School of Medicine, Albuquerque, USA.

Current Opinion in Hematology
|July 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving bone marrow biopsy quality through peer discussion and data comparisons: A single institution experience.

International journal of laboratory hematology·2018
Same author

High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL.

Leukemia·2016
Same author

Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements.

Leukemia·2013
Same author

VPREB1 deletions occur independent of lambda light chain rearrangement in childhood acute lymphoblastic leukemia.

Leukemia·2013
Same author

Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report.

Leukemia·2012
Same author

GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.

Leukemia·2011

Identifying prognostic markers in leukemia is crucial for risk-adapted therapies. Key factors like multidrug resistance and cytogenetics in acute myeloid leukemia, and growth control markers in acute lymphoblastic leukemia, predict patient outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Accurate prognosis is vital for tailoring treatments in hematopoietic malignancies.
  • Numerous prognostic factors are reported, but their clinical utility is often unclear due to study design limitations.

Purpose of the Study:

  • To highlight the importance of identifying reliable biologic markers for disease outcome in hematopoietic malignancies.
  • To emphasize the role of these markers in developing risk-adapted therapeutic strategies.

Main Methods:

  • Review of existing literature on prognostic factors in acute leukemias.
  • Analysis of variables influencing the prognostic value of biologic markers, including study size and patient treatment uniformity.

Main Results:

Related Experiment Videos

  • In acute myeloid leukemia, multidrug resistant phenotype and cytogenetics are significant prognostic indicators.
  • In acute lymphoblastic leukemia, markers of lost growth control, such as tumor suppressor gene loss and increased proliferation, identify poor-prognosis patients.

Conclusions:

  • Established prognostic factors enable better identification of patients who can benefit from risk-adapted therapies.
  • Continued research into prognostic markers is essential for advancing precision medicine in leukemia treatment.